About Disc Medicine
Disc Medicine is a publicly listed company based in Cambridge (United States) founded in 2017 by Brian Mac Donald. Developer of therapeutics for the treatment of hematologic diseases. Disc Medicine has raised $140 million across 4 funding rounds from investors including ARE, Orbimed and Janus Henderson Investors. The company has 84 employees. Its chief executive, as recorded, is Brian Mac Donald. Its website discmedicine.com draws about 13 thousand monthly visits. Disc Medicine offers products and services including Bitopertin, DISC-0974, and DISC-3405. Its focus areas include Life Sciences, Hematology, Drugs and Diversified. Its legal entity is Disc Medicine, Inc. Its competitors include Keros Therapeutics, Jasper Therapeutics and Interius Biotherapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Disc Medicine was founded in 2017 and is headquartered in Cambridge, United States. Focus is placed on developing therapeutic candidates that target fundamental pathways in red blood cell biology to address hematologic diseases. The product pipeline features Bitopertin, intended for erythropoietic porphyrias; DISC-0974, aimed at anemia associated with myelofibrosis; and matriptase-2, designed for myelodysplastic syndromes. Operations center on advancing these candidates through clinical development in the biotechnology sector.
- Headquarters Cambridge, United States
- Employees 84
- Founders Brian Mac Donald
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website discmedicine.com
- Social LinkedIn X
- Legal Name Disc Medicine, Inc.
- Net Profit-$212.18 M (USD)-94.03as on Dec 31, 2025
- EBITDA-$235.74 M (USD)-81.95as on Dec 31, 2025
- Total Equity Funding$140M (USD)
in 4 rounds
- Latest Funding Round$62.5M (USD), Post-IPO
Feb 2023
- InvestorsARE
& 11 more
- Employee Count84
Products & Services of Disc Medicine
Disc Medicine offers a comprehensive portfolio of products and services, including Bitopertin, DISC-0974, and DISC-3405.
Drug for treating erythropoietic protoporphyria by reducing PPIX levels
Candidate for hematologic diseases through targeted development
Therapy in development for blood disorder applications
Funding Insights of Disc Medicine
Disc Medicine has successfully raised a total of $140M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $62.5 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $140M
- Total Rounds 4
- Last Round Post-IPO — $62.5M
- Investors Count 12
All 4 funding rounds of Disc Medicine with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2023 | $62.5M | Post-IPO | – | Bain Capital Life Sciences | |
| Sep 2021 | $90M | Series B | – | Orbimed | |
| Oct 2019 | $50M | Series A | – | Novo Holdings | |
| Jun 2017 | Seed | – | Atlas Venture | – |
12 investors in total: 12 institutional.
Investors in Disc Medicine
Disc Medicine has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Orbimed and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are focused on pharmaceutical, biotechnology, and medical sectors. | baincapitallifesciences.com | Boston, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Investment and holding company controlled by Len Blavatnik | accessindustries.com | New York, United States | ||
Investments in biotech startups are made by Arix Bioscience. | 2016 | arixbioscience.com | London, United Kingdom | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Venture capital fund backed incubator focused on the healthcare startups | 5amventures.com | San Francisco, United States | ||
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Philanthropic assets are managed by Willett Advisors LLC. | willettadvisors.com | New York, United States | ||
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark |
Investor details for Disc Medicine
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Disc Medicine
57 people are tracked at Disc Medicine (35 in leadership, 14 in board & advisors, 8 in team); the tracked headcount is 84.
| Name | Role | Group |
|---|---|---|
Brian Mac Donald | Founder & CEO | Leadership |
Kevin Clarke | Executive Director, Strategic Accounts & Access | Leadership |
George Durrance | Director, Legal Operations and Contracts | Leadership |
Dan Monet | Vp, Commercial Operations | Leadership |
Rahul Rajan Kaushik | Chief Technical Officer | Leadership |
Steve Caffé | Chief Regulatory Officer | Leadership |
Jonathan Yu | Chief Operating Officer | Leadership |
Will Savage | Chief Medical Officer | Leadership |
Tara Condon | Director Of Field Operations | Leadership |
Gene Lichtman | Head Of Information Technology | Leadership |
Jason Cathelyn | Vice President, Intellectual Property | Leadership |
Amy Greenwood | Senior Director, Marketing | Leadership |
Derek Marion | Director Of Accounting | Leadership |
Sonia Razzetti | Senior Vice President Of Quality | Leadership |
John Quisel | Chief Executive Officer | Leadership |
Haley Howell | Executive Director, Clinical Development Operations | Leadership |
Melanie Chin | Vice President, Clinical Development And Head Of Medical Affairs | Leadership |
Angela Roster, ELS, MWC | Director, Medical Writing | Leadership |
Joe Saija | Director, Clinical Data Management | Leadership |
Katherine Watt Chan | Head of Portfolio and Program Management | Leadership |
37 more people are available in the full profile.
Complete people profiles for Disc Medicine
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Disc Medicine
Disc Medicine is a publicly listed company on the NASDAQ with ticker symbol IRON in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date29 Dec 2022
- Listed onNASDAQ: IRON
- Listed entityDisc Medicine, Inc.
- Exchange sectorHealth technology
- ISINUS2546041011
- Share price$56.60 (-6.42% on the day) · 2026-10-13
- Market capitalisation$2.17B
- EPS (diluted, trailing year)$-6.58
- Volume (last session)602,837
Financials of Disc Medicine
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$212.2M | -$235.7M | |
| 2024 | -$109.4M | -$129.6M | |
| 2023 | -$76.4M | -$91.0M | |
| 2022 | -$46.8M | -$47.2M | |
| 2021 | -$36.0M | -$30.7M |
Detailed financial statements for Disc Medicine
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Disc Medicine
4 dated milestones of Disc Medicine across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Disc Medicine is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $62.5M.
Competitors of Disc Medicine
Disc Medicine has 3 listed competitors in our database, 3 of them funded. They include Keros Therapeutics, Jasper Therapeutics and Interius Biotherapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kerostx.com | 2016 | Lexington, United States | $90M | 136 | Small molecules are developed to treat hematologic and musculoskeletal disorders. | |
| jaspertx.com | 1999 | Redwood, United States | $84.1M | Developer of therapeutics for chronic diseases by targeting mast cells and stem cells | ||
| interiusbio.com | 2020 | Philadelphia, United States | $129.03M | 25 | Developer of gene therapies for treating multiple diseases |
Detailed competitors of Disc Medicine
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Disc Medicine
The website of Disc Medicine (discmedicine.com) receives about 13.2K visits a month.
- Monthly visits13.2K
▲ 32.9% vs previous month
Top companies in Hematology
3 companies that operate in the same segment as Disc Medicine (Hematology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Catheter-based thrombectomy devices for vascular emboli removal are developed. | 2011 | Irvine, California, United States | USD 51.89 M | USD 493.63 M | 696 | |
Small molecules are developed to treat hematologic and musculoskeletal disorders. | 2016 | Lexington, Kentucky, United States | USD 90 M | USD 244.06 M | 169 | |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | 2016 | Menlo Park, California, United States | USD 300 M | 384 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Disc Medicine
Complete news archive for Disc Medicine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Disc Medicine
Disc Medicine was founded in 2017.
Disc Medicine is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Brian Mac Donald is the CEO of Disc Medicine, as recorded in our data. They have also founded this company.
Disc Medicine is a funded company, having raised a total of $140M across 4 funding rounds to date.
Disc Medicine has 84 employees.
Disc Medicine was founded in 2017 and is headquartered in Cambridge, United States. Focus is placed on developing therapeutic candidates that target fundamental pathways in red blood cell biology to address hematologic diseases. The product pipeline features Bitopertin, intended for erythropoietic porphyrias; DISC-0974, aimed at anemia associated with myelofibrosis; and matriptase-2, designed for myelodysplastic syndromes. Operations center on advancing these candidates through clinical development in the biotechnology sector.
Disc Medicine's top competitors include Keros Therapeutics, Jasper Therapeutics and Interius Biotherapeutics.
Disc Medicine offers Bitopertin, DISC-0974, and DISC-3405.
Yes, Disc Medicine is publicly traded on NASDAQ under the ticker symbol IRON.
Disc Medicine has 12 investors. Key investors include ARE, Orbimed, Janus Henderson Investors, Atlas Venture, and Arix Bioscience.
Disc Medicine operates through Disc Medicine, Inc..